Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

Guglielmetti L. Khan U. Velásquez G.E. Gouillou M. Ali M.H. Amjad S. Kamal F. Abubakirov A. Ardizzoni E. Baudin E. Bektassov S. Berry C. Bonnet M. Chavan V. Coutisson S. Dakenova Z. de Jong B.C. Dinh L.V. Ferlazzo G. Kirakosyan O. Lachenal N. Lecca L. McIlleron H. Mikanda K.K. Mucching-Toscano S. Mulders W. Mushtaque H. Nahid P. Nguyen D.V. Nguyen N.V. Oyewusi L. Motta I. Panda S. Patil S. Pham T.H. Phan D.T. Phan H.T.T. Phillips P.P.J. Ruiz J. Rupasinghe P. Salahuddin N. Sanchez-Garavito E. Seung K.J. Asfaw M.T. Vargas Vasquez D. Rich M.L. Varaine F. Mitnick C.D.
September 2025 Elsevier Ltd

The Lancet Respiratory Medicine
2025 #13 Issue 9 809 - 820 pp.

Background: Pre-extensively drug-resistant (pre-XDR) tuberculosis (ie, multidrug-resistant or rifampicin-resistant with additional resistance to any fluoroquinolone) is difficult to treat. endTB-Q aimed to evaluate the efficacy and safety of bedaquiline, delamanid, linezolid, and clofazimine (BDLC) compared with the standard of care for patients with pre-XDR tuberculosis. Methods: This open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial was conducted in ten hospitals in India, Kazakhstan, Lesotho, Pakistan, Peru, and Viet Nam. Participants aged 15 years or older who had pulmonary tuberculosis with resistance to rifampicin and fluoroquinolones were included. Participants were randomly assigned (2:1) to the BDLC group (all-oral bedaquiline 400 mg once per day for 2 weeks followed by 200 mg three times per week, delamanid 100 mg twice per day, linezolid 600 mg once per day for 16 weeks and then either 300 mg once per day or 600 mg three times per week, and clofazimine 100 mg once per day) or the control group (individualised WHO-recommended longer standard of care). Randomisation was stratified by country and baseline disease extent. BDLC was administered for 39 weeks (9-month regimen) for extensive disease and 24 weeks (6-month regimen) for limited disease and extended to 9 months for those with a positive culture at 8 weeks or later or a missing 8-week culture result. Site staff and participants were not masked, whereas investigators and laboratory staff were masked to treatment assignment. The primary endpoint was favourable outcome (two consecutive, negative cultures including one between weeks 65 and 73; or favourable bacteriological, radiological, and clinical evolution) at week 73 after randomisation in the modified intention-to-treat (mITT) and per-protocol populations. We report the risk differences adjusted for stratification variables, with a non-inferiority margin of –12%. This trial is registered with ClinicalTrials.gov, NCT03896685. Findings: Between April 4, 2020, and March 28, 2023, 1030 individuals were screened and 324 (31%) were randomly assigned (219 to the BDLC group and 105 to the control group). 114 (46%) participants were female and 133 (54%) were male. Median age was 30·5 years (IQR 21·6–43·0). 157 (64%) participants had extensive disease at baseline. In the BDLC group, 47 (29%) of 163 were assigned to receive the 6-month regimen and 116 (71%) the 9-month regimen. The core regimen of BDLC plus one or more other drugs was used for 76 (91%) of 84 participants in the control group. At week 73, favourable outcome was reached by 141 (87%) participants in the BDLC group versus 75 (89%) in the control group in the mITT population (adjusted risk difference 0·2% [95% CI –9·1 to 9·5]; p_{non-inferiority}=0·0051) and by 138 (88%) of 157 versus 71 (93%) of 76 in the per-protocol population (adjusted risk difference –3·5% [–12·8 to 5·9]; p_{non-inferiority}=0·037). Overall non-inferiority was not shown. 145 (68%) of 213 participants in the BDLC group and 77 (73%) of 105 in the control group had at least one grade 3 or higher adverse event, with eight (4%) and two (2%) all-cause deaths by week 73, respectively. Interpretation: The shortened BDLC strategy was not non-inferior to the control. Accumulating evidence suggests that this patient population might require longer, reinforced regimens. Funding: Unitaid, Médecins Sans Frontières, Partners In Health, Interactive Research and Development, Ramón Areces Foundation, the Jung Foundation for Science and Research, Research Foundation-Flanders. Translations: For the Hindi, Marathi, Spanish, Vietnamese, Russian, Urdu and French translations of the abstract see Supplementary Materials section.

Text of the article Перейти на текст статьи

Médecins Sans Frontières, Paris, France
Department of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Verona, Italy
Interactive Research and Development Global, Singapore
Department of Epidemiology, Biostatistics, and Occupational Health, McGill University Montreal, Montreal, QC, Canada
Center for Tuberculosis, Institute for Global Health Sciences, University of California, San Francisco, CA, United States
Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, United States
Hospital Nacional Hipólito Unanue, El Agustino, Peru
Socios en Salud-Sucursal, San Isidro, Peru
Médecins Sans Frontières, London, United Kingdom
Hanoi Lung Hospital, Hanoi, Viet Nam
Partners In Health Lesotho, Maseru, Lesotho
Partners In Health, Boston, MA, United States
Division of Global Health Equity, Brigham and Womens Hospital, MA, United States
Hospital Nacional Sergio E Bernales, Comas, Peru
The Indus Hospital and Health Network, Karachi, Pakistan
Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
National AIDS Research Institute, Pune, India
Indian Council of Medical Research, New Delhi, India
MRC Clinical Trials Unit, UCL, London, United Kingdom
Global Health and Social Medicine, Harvard Medical School, Boston, MA, United States
Department of Medicine, University of Cape Town, Cape Town, South Africa
Médecins Sans Frontières, Geneva, Switzerland
Department of Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Borstel, Germany
Interactive Research and Development, Karachi, Pakistan
Vietnam National TB Program University of California San Francisco Research Collaboration Unit, Center for Promotion of Advancement of Society Hanoi, Hanoi, Viet Nam
Epicentre, Paris, France
National Lung Hospital, Hanoi, Viet Nam
Pham Ngoc Thach Hospital, Ho Chi Minh City, Viet Nam
City Center of Phthisiopulmonology, Astana, Kazakhstan
Médecins Sans Frontières, Mumbai, India
Translational Research on HIV and Endemic and Emerging Infectious Diseases, Montpellier Université de Montpellier, Institut de Recherche pour le Développement, INSERM, Montpellier, France
National Scientific Center of Phthisiopulmonology, Almaty, Kazakhstan

Médecins Sans Frontières
Department of Infectious
Interactive Research and Development Global
Department of Epidemiology
Center for Tuberculosis
Division of HIV
Hospital Nacional Hipólito Unanue
Socios en Salud-Sucursal
Médecins Sans Frontières
Hanoi Lung Hospital
Partners In Health Lesotho
Partners In Health
Division of Global Health Equity
Hospital Nacional Sergio E Bernales
The Indus Hospital and Health Network
Department of Biomedical Sciences
National AIDS Research Institute
Indian Council of Medical Research
MRC Clinical Trials Unit
Global Health and Social Medicine
Department of Medicine
Médecins Sans Frontières
Department of Clinical Infectious Diseases
Interactive Research and Development
Vietnam National TB Program University of California San Francisco Research Collaboration Unit
Epicentre
National Lung Hospital
Pham Ngoc Thach Hospital
City Center of Phthisiopulmonology
Médecins Sans Frontières
Translational Research on HIV and Endemic and Emerging Infectious Diseases
National Scientific Center of Phthisiopulmonology

10 лет помогаем публиковать статьи Международный издатель

Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026